4.7 Article

Dentithecamides A-H, Diacylated Zoanthoxanthin Derivatives with PAX3-FOXO1 Inhibitory Activity from the Hydroid Dentitheca habereri

Journal

JOURNAL OF NATURAL PRODUCTS
Volume 85, Issue 5, Pages 1419-1427

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jnatprod.2c00246

Keywords

-

Funding

  1. Natural Products Support Group (NCI at Frederick)
  2. National Natural Science Foundation of China [81903772]
  3. Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
  4. National Cancer Institute, National Institutes of Health [HHSN261200800001E]

Ask authors/readers for more resources

Chemical investigation of the marine hydroid Dentitheca habereri led to the discovery of eight new zoanthoxanthin alkaloids, which are the first to be reported from a hydroid. Some of these compounds show potential in inhibiting PAX3-FOXO1 transcriptional activity, making them potential candidates for drug development.
Chemical investigation of the marine hydroid Dentitheca habereri led to the identification of eight new diacylated zoanthoxanthin alkaloids, named dentithecamides A-H (1-8), along with three previously reported analogues, zoamides B-D (9-11). The structures of compounds 1-11 were elucidated by spectroscopic and spectrometric analyses, including IR, HRESIMS, and NMR experiments, and by comparison with literature data. Compounds 1-11 are the first zoanthoxanthin alkaloids to be reported from a hydroid. Dentithecamides A (1) and B (2) along with zoamides B-D (9-11), which all share a conformationally mobile cycloheptadiene core, inhibited PAX3-FOXO1 regulated transcriptional activity and thus provided a structural framework for the potential development of more potent PAX3-FOXO1 inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available